Breakthrough in targeted therapy for non -small cell lung cancer

被引：91

作者：

Ye, Zhencong ^{[1
,2
]}

Huang, Yongmei ^{[1
,2
,3
,4
]}

Ke, Jianhao ^{[5
]}

Zhu, Xiao ^{[1
,2
,3
,4
]}

Leng, Shuilong ^{[6
]}

Luo, Hui ^{[1
,2
,3
,4
]}

机构：

[1] Southern Marine Sci & Engn Guangdong Lab Zhanjian, Zhanjiang, Peoples R China

[2] Guangdong Med Univ, Marine Biomed Res Inst, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China

[3] Guangdong Med Univ, Key Lab Zhanjiang R&D Marine Microbial Resources, Zhanjiang, Peoples R China

[4] Marine Biomed Res Inst Guangdong Zhanjiang, Zhanjiang, Peoples R China

[5] South China Agr Univ, Coll Agr, Guangzhou, Peoples R China

[6] Guangzhou Med Univ, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Sch Basic Med Sci, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2021年 / 133卷

基金：

中国国家自然科学基金;

关键词：

Non-small cell lung cancer; Targeted therapy; Chemotherapy; EGFR; ALK; EPITHELIAL-MESENCHYMAL TRANSITION; OPEN-LABEL; 1ST-LINE TREATMENT; PHASE-III; ACQUIRED-RESISTANCE; SIGNALING PATHWAY; RET; GEFITINIB; GENE; ADENOCARCINOMA;

D O I：

10.1016/j.biopha.2020.111079

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.

引用

页数：10

共 111 条

[1] RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome [J].

Abbar, Baptiste ;

Henry, Carole ;

Theou-Anton, Nathalie ;

Brosseau, Solenn ;

Nguenang, Marina ;

Pluvy, Johan ;

Assoun, Sandra ;

Zalcman, Gerard ;

Gounant, Valerie .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) :E250-E251

[2] High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study [J].

Baldacci, Simon ;

Figeac, Martin ;

Antoine, Martine ;

Descarpentries, Clotilde ;

Kherrouche, Zoulika ;

Jamme, Philippe ;

Copin, Marie-Christine ;

Tulasne, David ;

Nanni, Isabelle ;

Beau-Faller, Michele ;

Melaabi, Samia ;

Levallet, Guenaelle ;

Quoix, Elisabeth ;

Moro-Sibilot, Denis ;

Friard, Sylvie ;

Missy, Pascale ;

Barlesi, Fabrice ;

Cadranel, Jacques ;

Cortot, Alexis B. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) :120-124

[3]

Barlesi F., 2019, ANN ONCOL, V30, pii48

[4] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[5] Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer [J].

Blackhall, Fiona ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Soria, Jean-Charles ;

Solomon, Benjamin J. ;

Mok, Tony ;

Hirsh, Vera ;

Jaenne, Pasi A. ;

Shi, Yuankai ;

Yang, Pan-Chyr ;

De Pas, Tommaso ;

Hida, Toyoaki ;

De Castro Carpeno, Javier ;

Lanzalone, Silvana ;

Polli, Anna ;

Iyer, Shrividya ;

Reisman, Arlene ;

Wilner, Keith D. ;

Kim, Dong-Wan .

ESMO OPEN, 2017, 2 (03)

[6] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) [J].

Blumenschein, G. R., Jr. ;

Smit, E. F. ;

Planchard, D. ;

Kim, D. -W. ;

Cadranel, J. ;

De Pas, T. ;

Dunphy, F. ;

Udud, K. ;

Ahn, M. -J. ;

Hanna, N. H. ;

Kim, J. -H. ;

Mazieres, J. ;

Kim, S. -W. ;

Baas, P. ;

Rappold, E. ;

Redhu, S. ;

Puski, A. ;

Wu, F. S. ;

Jaenne, P. A. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :894-901

[7] Targeting RET-rearranged non-small-cell lung cancer: future prospects [J].

Bronte, Giuseppe ;

Ulivi, Paola ;

Verlicchi, Alberto ;

Cravero, Paola ;

Delmonte, Angelo ;

Crino, Lucio .

LUNG CANCER-TARGETS AND THERAPY, 2019, 10 :27-36

[8] Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy [J].

Bruera, Gemma ;

D'Andrilli, Antonio ;

Simmaco, Maurizio ;

Guadagni, Stefano ;

Rendina, Erino Angelo ;

Ricevuto, Enrico .

FRONTIERS IN ONCOLOGY, 2020, 10

[9] Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial [J].

Camidge, D. Ross ;

Kim, Hye Ryun ;

Ahn, Myung-Ju ;

Yang, James C. H. ;

Han, Ji-Youn ;

Hochmair, Maximilian J. ;

Lee, Ki Hyeong ;

Delmonte, Angelo ;

Garcia Campelo, Maria Rosario ;

Kim, Dong-Wan ;

Griesinger, Frank ;

Felip, Enriqueta ;

Califano, Raffaele ;

Spira, Alexander ;

Gettinger, Scott N. ;

Tiseo, Marcello ;

Lin, Huamao M. ;

Gupta, Neeraj ;

Hanley, Michael J. ;

Ni, Quanhong ;

Zhang, Pingkuan ;

Popat, Sanjay .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) :3592-+

[10] Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study [J].

Camidge, D. Ross ;

Dziadziuszko, Rafal ;

Peters, Solange ;

Mok, Tony ;

Noe, Johannes ;

Nowicka, Malgorzata ;

Gadgeel, Shirish M. ;

Cheema, Parneet ;

Pavlakis, Nick ;

de Marinis, Filippo ;

Cho, Byoung Chul ;

Zhang, Li ;

Moro-Sibilot, Denis ;

Liu, Ting ;

Bordogna, Walter ;

Balas, Bogdana ;

Mueller, Barbara ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1233-1243

← 1 2 3 4 5 6 7 8 9 10 →